Home › Research › Clinical trials
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM, for the TRAILBLAZER-ALZ 2 Investigators. JAMA, 2023-07-17
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
This is the pivotal Phase 3 trial for donanemab in 1,736 people with early symptomatic Alzheimer's. Donanemab slowed decline on a combined cognitive/functional scale (iADRS) by about 22-35% relative to placebo over 76 weeks, depending on tau levels at baseline. Brain swelling (ARIA-E) occurred in 24% of donanemab patients vs 2.1% on placebo, and small brain bleeds (ARIA-H) in 31.4% vs 13.6%; three deaths in the donanemab group were considered treatment-related.
What this study adds
Evidence grade: Moderate
The record lists 1,736 participants. In the Phase 3 TRAILBLAZER-ALZ 2 trial, donanemab slowed decline on a combined cognitive/functional scale by about 22-35% relative to placebo over 76 weeks, depending on baseline tau levels. Reported effect size: iADRS decline slowed by 35.1% (low/medium-tau participants) and 22.3% (combined population) vs. placebo.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Sims, JR., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., et al. (2023). Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2023.13239
Vancouver
Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023. doi:10.1001/jama.2023.13239. PMID: 37459141.
BibTeX
@article{sims2023-9857475c,
author = {Sims, JR. and Zimmer, J. A. and Evans, C. D. and Lu, M. and Ardayfio, P. and Sparks, J. and Wessels, A. M. and Shcherbinin, S. and Wang, H. and Monkul Nery, E. S. and Collins, E. C. and Solomon, P. and Salloway, S. and Apostolova, L. G. and Hansson, O. and Ritchie, C. and Brooks, D. A. and Mintun, M. and Skovronsky, D. M. and {TRAILBLAZER-ALZ 2 Investigators}},
title = {{Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial}},
journal = {JAMA},
year = {2023},
doi = {10.1001/jama.2023.13239},
pmid = {37459141},
url = {https://doi.org/10.1001/jama.2023.13239}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 20 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- n=1,736 (860 donanemab, 876 placebo); 76-week Phase 3 trial across 277 sites in 8 countries
- iADRS slowing of 35.1% in low/medium-tau participants and 22.3% in the combined population vs placebo (both p<.001)
- ARIA-E in 24.0% (donanemab) vs 2.1% (placebo); ARIA-H in 31.4% vs 13.6%; 3 donanemab-group deaths judged treatment-related vs 1 in placebo group
Why it matters
In the Phase 3 TRAILBLAZER-ALZ 2 trial, donanemab slowed decline on a combined cognitive/functional scale by about 22-35% relative to placebo over 76 weeks, depending on baseline tau levels. Brain swelling occurred in 24% of donanemab patients versus 2.1% on placebo, and three deaths in the donanemab group were considered treatment-related.
New to this subject? Start with our plain-English guide: Registered clinical trials →
Study details
- Study designphase-3-trial
- Participants1,736
- Effect sizeiADRS decline slowed by 35.1% (low/medium-tau participants) and 22.3% (combined population) vs. placebo
- Evidence strengthModerate
Limitations
ARIA-E in 24.0% vs. 2.1% placebo, ARIA-H in 31.4% vs. 13.6%; 3 donanemab-group deaths judged treatment-related; population pre-selected for confirmed amyloid and intermediate/high tau, limiting generalizability.
How this study scored 77/100
Published in a top-tier journal, and it is a large phase 3 trial. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 48 of the 62 points we could judge it on, which is 77 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 10 / 10 | Tier 1 — top-tier general journal (JAMA) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 11 / 12 | A large phase 3 trial |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 3 / 4 | 1,736 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 37459141) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 48 / 62 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 48 of the 62 points we could judge it on is 77 out of 100. |
| Total | 77 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 16.
In the news
1 news article on alzhub's news page cites this paper.
Later studies that cite this one
271 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Clinical trials from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.